Format

Send to

Choose Destination
Infect Dis Ther. 2018 Dec;7(4):473-484. doi: 10.1007/s40121-018-0218-x. Epub 2018 Oct 27.

Pan-Genotypic Hepatitis C Treatment with Glecaprevir and Pibrentasvir for 8 Weeks Resulted in Improved Cardiovascular and Metabolic Outcomes and Stable Renal Function: A Post-Hoc Analysis of Phase 3 Clinical Trials.

Author information

1
Liver Disease and Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
2
Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA.
3
AbbVie Inc., North Chicago, IL, USA.
4
AbbVie Inc., North Chicago, IL, USA. yuri.sanchezgonzalez@abbvie.com.

Abstract

INTRODUCTION:

Chronic hepatitis C (CHC) infection is associated with extrahepatic manifestations (EHMs) which can affect renal, cardiovascular and other comorbidities. The effect of CHC treatment with short-duration regimens on these EHMs is not well defined. Hence, we examined longitudinal estimated glomerular filtration rate (eGFR), triglycerides and glucose values to assess the impact of short-duration CHC therapy on renal, cardiovascular and metabolic diseases, respectively.

METHODS:

We conducted analyses of all patients without cirrhosis treated with glecaprevir and pibrentasvir (G/P) for 8 weeks in two phase 3 clinical trials. In addition, one phase 3 trial was carried out to explore the effects of treatment on renal EHMs in patients with advanced renal impairment at baseline. As a sensitivity analysis, we included all CHC patients treated with G/P for 8 or 12 weeks enrolled across five phase 3 trials. Adjusting for baseline demographics and clinical properties via mixed regression models enabled evaluation of changes in EHMs through end of treatment.

RESULTS:

G/P treatment for 8 weeks resulted in statistically significant declines in triglycerides (- 28.6 mg/dl) and glucose (- 11.2 mg/dl), while there was no statistically significant decline in eGFR. Biomarker improvements were greatest among patients with elevated triglycerides and elevated glucose at baseline. Similar effects were observed across all patients treated with G/P for 8 or 12 weeks.

CONCLUSION:

Short-duration treatment with G/P resulted in stable renal function and improvements in cardiovascular and metabolic EHM markers, especially in patients with severe EHMs at baseline.

FUNDING:

AbbVie Inc.

KEYWORDS:

Extrahepatic manifestations; Glecaprevir; Glucose; Hepatitis C; Pibrentasvir

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center